Nelarabine (Atriance®) for the treatment of T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000417
English
Authors' recommendations:
Nelarabine (Atriance®) is recommended for restricted use within NHS Wales for the treatment of patients with T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to, or has relapsed, following treatment with at least two chemotherapy regimens. Treatment should be restricted to patients in whom there is an intention to proceed to allogeneic stem cell transplantation, as it is not cost effective when used for palliation.
Nelarabine (Atriance®) is not suitable for shared care within NHS Wales.
Details
Project Status:
Completed
Year Published:
2009
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=121849&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Arabinonucleosides
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia-Lymphoma, Adult T-Cell
- Antineoplastic Agents
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.